With expertise in blending, dry and wet granulation, tablet compression, coating, encapsulation, and more, we deliver immediate or modified release forms across tablets, capsules, minitablets, granules, and pellets. Phaseappropriate, science-driven, risk-based process development, technology transfers, and analytical support ensure smooth scale-up from hundreds of grams to commercial production, meeting global regulatory standards. Working closely with our Solid State Centre of Excellence, we provide fully integrated API and Drug Product services, creating a continuous feedback loop to identify the optimal API form for absorption, solubility, stability, and processability. From developability assessments to technology selection, screening studies, prototype development, and Accelerated Stability Assessment Programs (ASAP), we move products efficiently into First-in-Human (FIH) studies and beyond. Our oral peptide delivery services complement robust peptide drug substance offerings, providing end-to-end integrated supply. Absorption is enhanced through strategies such as increased lipophilicity, reduced degradation, and improved membrane permeability, combined with formulation technologies including permeation enhancers, SMEDDS, and LNP carriers. These capabilities ensure reliable progression from early development through commercial supply. 18 Dr. STEPHEN HOULDSWORTH Global Head, Small Molecules Platform CordenPharma International Visit CordenPharma at CPHI Frankfurt 2025 Stand 6.0A24 to learn more! (CordenPharma Photo) Fluid bed processing for Small Molecule OSD manufacturing at CordenPharma Plankstadt (DE). DAILY NEWS CPHI 2025 FRANKFURT DAY 1 | 28th October 2025 CordenPharma Small Molecules Technology Platform Highly Potent & Oncology Technology Platform Read more about our bioavailability enhancement
RkJQdWJsaXNoZXIy MjY2OTA4MA==